Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rank in Stocks #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in MalmΓΆ, Sweden.
Share Price
$0.00162013
Last synced: 2025-01-03
Market Cap
$156.25K
Change (1 day)
0.36%
Change (1 year)
0.00%
Country
SE
Trade Cyxone AB (publ) (CYXO)

Category

Earnings for Cyxone AB (publ) (CYXO)
Earnings in Jun 2024 TTM: $-2.04M
According to Cyxone AB (publ) latest financial reports the company's current earnings are $-2.04M. In 2022 the company made an earning of $-4.07M, an increase over its 2021 earnings that were of $-4.98M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Cyxone AB (publ) from 2015 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-2.04M -10.32%
2023 $-2.28M -44.05%
2022 $-4.07M -18.14%
2021 $-4.98M -16.09%
2020 $-5.93M 57.40%
2019 $-3.77M 118.05%
2018 $-1.73M 60.09%
2017 $-1.08M 135.58%
2016 $-458.07K -2,484.88%
2015 $19.21K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -258,252.37%
US
$1.95B -95,564.36%
NL
- -
CH
- -
KR
$3.01B -147,199.10%
BE